Research Brief
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Lynn Bjerke, Alan Mackay, Meera Nandhabalan, Anna Burford, Alexa Jury, Sergey Popov, Dorine A. Bax, Diana Carvalho, Kathryn R. Taylor, Maria Vinci, Ilirjana Bajrami, Imelda M. McGonnell, Christopher J. Lord, Rui M. Reis, Darren Hargrave, Alan Ashworth, Paul Workman and Chris Jones
Lynn Bjerke
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Alan Mackay
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Meera Nandhabalan
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Anna Burford
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Alexa Jury
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Sergey Popov
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Dorine A. Bax
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Diana Carvalho
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Kathryn R. Taylor
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Maria Vinci
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Ilirjana Bajrami
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Imelda M. McGonnell
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Christopher J. Lord
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Rui M. Reis
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Darren Hargrave
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Alan Ashworth
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Paul Workman
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
Chris Jones
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
DOI: 10.1158/2159-8290.CD-12-0426 Published May 2013

Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 3, Issue 5, pp. 512-519
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 20, 2012
- Revision received January 25, 2013
- Accepted January 28, 2013
- Published first March 28, 2013.
Article Versions
- Previous version (March 28, 2013 - 06:45).
- You are viewing the most recent version of this article.
Copyright & Usage
©2013 American Association for Cancer Research.
Author Information
- Lynn Bjerke1,2,
- Alan Mackay1,2,
- Meera Nandhabalan1,2,
- Anna Burford1,2,
- Alexa Jury1,2,
- Sergey Popov1,2,
- Dorine A. Bax1,2,
- Diana Carvalho1,2,6,7,
- Kathryn R. Taylor1,2,
- Maria Vinci1,2,
- Ilirjana Bajrami1,3,
- Imelda M. McGonnell4,
- Christopher J. Lord1,3,
- Rui M. Reis7,8,
- Darren Hargrave5,
- Alan Ashworth1,3,
- Paul Workman2 and
- Chris Jones1,2
- Authors' Affiliations: 1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil
- Corresponding Author:
Chris Jones, Glioma Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom. Phone: 44-020-8722-4416; Fax: 44-020-8722-4321; E-mail: chris.jones{at}icr.ac.uk
May 2013
Volume 3, Issue 5
Volume 3, Issue 5
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Lynn Bjerke, Alan Mackay, Meera Nandhabalan, Anna Burford, Alexa Jury, Sergey Popov, Dorine A. Bax, Diana Carvalho, Kathryn R. Taylor, Maria Vinci, Ilirjana Bajrami, Imelda M. McGonnell, Christopher J. Lord, Rui M. Reis, Darren Hargrave, Alan Ashworth, Paul Workman and Chris Jones
Cancer Discov May 1 2013 (3) (5) 512-519; DOI: 10.1158/2159-8290.CD-12-0426
Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Lynn Bjerke, Alan Mackay, Meera Nandhabalan, Anna Burford, Alexa Jury, Sergey Popov, Dorine A. Bax, Diana Carvalho, Kathryn R. Taylor, Maria Vinci, Ilirjana Bajrami, Imelda M. McGonnell, Christopher J. Lord, Rui M. Reis, Darren Hargrave, Alan Ashworth, Paul Workman and Chris Jones
Cancer Discov May 1 2013 (3) (5) 512-519; DOI: 10.1158/2159-8290.CD-12-0426
Jump to section
Advertisement